hackint0sh/temp-data huggingface dataset:
protocolSection identificationModule nctId: NCT06297824, orgStudyIdInfo id: 2023-04909-01, briefTitle: Feasibility of Emotion Regulation Group Therapy for Adolescent Self-Harm, acronym: ERGT-A, statusModule overallStatus: RECRUITING, startDateStruct date: 2023-10-10, primaryCompletionDateStruct date: 2024-12-31, completionDateStruct date: 2025-06-30, studyFirstPostDateStruct date: 2024-03-07, lastUpdatePostDateStruct date: 2024-03-07, sponsorCollaboratorsModule leadSponsor name: Karolinska Institutet, class: OTHER, descriptionModule briefSummary: Deliberate self-harm (DSH) is a prevalent behaviour among adolescents but there is no current recommendation for an efficacious treatment. Emotion regulation group therapy (ERGT) is a brief treatment for DSH with a well-documented utility and feasibility in the adult population, and an adapted version for adolescents may provide equal benefits for adolescents, provided adjustments to prevent or decrease social contagion are present.A quantitative feasibility open trial (N=20) followed up by a qualitative interview study will examine the feasibility, acceptability and preliminary effect of ERGT for adolescents., conditionsModule conditions: Self-harm, conditions: Emotion Regulation, conditions: Adolescent - Emotional Problem, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, interventionModelDescription: Feasibility, open trial, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 20, type: ESTIMATED, armsInterventionsModule interventions name: ERGT-A, outcomesModule primaryOutcomes measure: Feasibility measure, recruitment rate, primaryOutcomes measure: Feasibility measures, proportion included, primaryOutcomes measure: Feasibility measures, compliance, primaryOutcomes measure: Feasibility measures, attrition, primaryOutcomes measure: Feasibility measures, client satisfaction, primaryOutcomes measure: Feasibility measures, negative effects of treatment, secondaryOutcomes measure: Preliminary effect, self harm frequency EOT, secondaryOutcomes measure: Preliminary effect, self harm frequency 1MFU, secondaryOutcomes measure: Preliminary effect, emotion dysregulation EOT, secondaryOutcomes measure: Preliminary effect, emotion dysregulation 1MFU, eligibilityModule sex: ALL, minimumAge: 13 Years, maximumAge: 17 Years, stdAges: CHILD, contactsLocationsModule locations facility: Prima Barn och Vuxenpsykiatri Handen och Järva, status: RECRUITING, city: Stockholm, state: Spånga, zip: 16374, country: Sweden, contacts name: Dimitar Krastev, MSc, role: CONTACT, phone: +46735269516, email: Dimitar.Krastev@prima.se, contacts name: MaiBritt Giacobini, PhD, role: CONTACT, phone: +46709736662, email: Maibritt.Giacobini@prima.se, geoPoint lat: 59.33258, lon: 18.0649, hasResults: False
protocolSection identificationModule nctId: NCT06297811, orgStudyIdInfo id: SMA PT 001, briefTitle: Myeloprotection With Trilaciclib in Pan-cancer Population, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-03-01, primaryCompletionDateStruct date: 2025-09-30, completionDateStruct date: 2027-12-31, studyFirstPostDateStruct date: 2024-03-07, lastUpdatePostDateStruct date: 2024-03-07, sponsorCollaboratorsModule leadSponsor name: Sun Yat-sen University, class: OTHER, descriptionModule briefSummary: The goal of this open-label randomized controlled study is to assess the myeloprotective effect of trilaciclib in pan-cancer population. The main questions it aims to answer are:* effect and safety of trilaciclib on myeloprotection in cancer patients receiving paclitaxel plus carboplatin chemotherapy* does trilaciclib 's myeloprotective efficacy in patients receiving the same chemotherapy regimen correlate with tumor typeParticipants will be randomized 2:1 to the treatment arm of trilaciclib in combination with a paclitaxel and carboplatin-based regimen and the control arm of a paclitaxel and carboplatin-based regimen for at least 6 cycles or until disease progression or intolerable toxicity. Patients in both groups could extend the chemotherapy cycle at the investigator 's discretion depending on the tumor type and in combination with anti-angiogenic/PD-X/anti-HER2 therapy., conditionsModule conditions: Non-Small Cell Lung Cancer, conditions: Breast Cancer, conditions: Endometrial Cancer, conditions: Cervical Cancer, conditions: Head And Neck Squamous Cell Carcinomas, designModule studyType: INTERVENTIONAL, phases: PHASE2, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: PREVENTION, maskingInfo masking: NONE, enrollmentInfo count: 132, type: ESTIMATED, armsInterventionsModule interventions name: Trilaciclib Injection, interventions name: Paclitaxel, interventions name: Carboplatin, outcomesModule primaryOutcomes measure: Occurrence of grade 3/4 neutropenia within 6 cycles, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Medical Oncology,Sun Yat-sen University Cancer Center, city: Guangzhou, state: Guangdong, zip: 510060, country: China, geoPoint lat: 23.11667, lon: 113.25, hasResults: False
protocolSection identificationModule nctId: NCT06297798, orgStudyIdInfo id: SakaryaAppliedSciencesUPNS, briefTitle: Effects of Telerehabilitation-Based Interventions on the Musculoskeletal System in Drivers, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-03-14, primaryCompletionDateStruct date: 2024-03-21, completionDateStruct date: 2024-05-10, studyFirstPostDateStruct date: 2024-03-07, lastUpdatePostDateStruct date: 2024-03-15, sponsorCollaboratorsModule leadSponsor name: Sakarya Applied Sciences University, class: OTHER, descriptionModule briefSummary: This study is designed to examine the effect of telerehabilitation application on the musculoskeletal system of drivers.The study will include 40 voluntary participants who work as drivers on inter-district routes in Sakarya. The participants' sociodemographic information, musculoskeletal problems, and postures will be assessed. Participants will be divided into two groups: one group will receive tele-rehabilitation with posture and stabilization exercises, while the other group will serve as the control group. The exercises will be implemented for 10 weeks, followed by an 8-week tapering period, after which the groups will be crossed over. A re-evaluation will be conducted after 10 weeks, with follow-up assessments scheduled for 3 months later., conditionsModule conditions: Drive, conditions: Musculoskeletal Diseases, conditions: Postural; Defect, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: CROSSOVER, primaryPurpose: TREATMENT, maskingInfo masking: SINGLE, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 40, type: ESTIMATED, armsInterventionsModule interventions name: Telerehabilitation, outcomesModule primaryOutcomes measure: MUSCLE SKELETAL SYSTEM ASSESSMENT, secondaryOutcomes measure: Posture Measures, eligibilityModule sex: MALE, minimumAge: 30 Years, maximumAge: 65 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Sakarya University of Applied Sciences, city: Sakarya, zip: 54000, country: Turkey, contacts name: Nurgul SEN, Master's degree, role: CONTACT, phone: 05344527440, email: pakizesen@subu.edu.tr, contacts name: Ceyhun TURKMEN, Assoc. Prof., role: PRINCIPAL_INVESTIGATOR, hasResults: False
protocolSection identificationModule nctId: NCT06297785, orgStudyIdInfo id: 2022-03997-01, briefTitle: Online, Gut-directed Hypnotherapy for Patients With Irritable Bowel Syndrome (IBS), statusModule overallStatus: RECRUITING, startDateStruct date: 2022-10-17, primaryCompletionDateStruct date: 2027-04, completionDateStruct date: 2027-04, studyFirstPostDateStruct date: 2024-03-07, lastUpdatePostDateStruct date: 2024-03-07, sponsorCollaboratorsModule leadSponsor name: Sahlgrenska University Hospital, Sweden, class: OTHER, descriptionModule briefSummary: Adult IBS patients with symptoms refractory to standard medical treatment will receive online nurse-administered, gut-directed hypnotherapy in groups. The primary outcome measure was change in gastro-intestinal symptom severity., conditionsModule conditions: IBS - Irritable Bowel Syndrome, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 50, type: ESTIMATED, armsInterventionsModule interventions name: Gut-directed hypnotherapy, outcomesModule primaryOutcomes measure: Change in gastrointestinal symptom severity, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 75 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Mag-Tarmlab, Sahlgrenska University Hospital, status: RECRUITING, city: Gothenburg, zip: 41345, country: Sweden, contacts name: Jenny Lövdahl, role: CONTACT, phone: 0313428107, email: magtarmlab.su@vgregion.se, geoPoint lat: 57.70716, lon: 11.96679, locations facility: Sahlgrenska University Hospital, status: RECRUITING, city: Gothenburg, zip: 41345, country: Sweden, geoPoint lat: 57.70716, lon: 11.96679, hasResults: False
protocolSection identificationModule nctId: NCT06297772, orgStudyIdInfo id: RJBMT-003, briefTitle: Compare the Efficacy and Safety of Dec-FB4 and FB4 as Conditioning Regimen for AML-MR, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04-01, primaryCompletionDateStruct date: 2026-03-01, completionDateStruct date: 2028-05-01, studyFirstPostDateStruct date: 2024-03-07, lastUpdatePostDateStruct date: 2024-03-13, sponsorCollaboratorsModule leadSponsor name: Ruijin Hospital, class: OTHER, descriptionModule briefSummary: A multicenter, randomized, controlled clinical study comparing the efficacy and safety of allogeneic hematopoietic stem cell transplantation with decitabine-Fludarabine- busulfan (Dec-FB4) and Fludarabine-busulfan (FB4) as pretreatment regimens for the treatment of acute myeloid leukemia in adults with MR gene abnormalities, conditionsModule conditions: AML, Adult, designModule studyType: INTERVENTIONAL, phases: PHASE3, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 220, type: ESTIMATED, armsInterventionsModule interventions name: Decitabine, interventions name: Fludarabine Injection, interventions name: Busulfan Injection, outcomesModule primaryOutcomes measure: disease-free survival, secondaryOutcomes measure: incidence of relapse rate, secondaryOutcomes measure: Non-recurrent mortality, eligibilityModule sex: ALL, minimumAge: 16 Years, maximumAge: 65 Years, stdAges: CHILD, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Ruijin Hospital, city: Shanghai, zip: 200025, country: China, contacts name: Xiaoxia Hu, role: CONTACT, phone: 862164370045, email: hxx12276@rjh.com.cn, geoPoint lat: 31.22222, lon: 121.45806, hasResults: False
protocolSection identificationModule nctId: NCT06297759, orgStudyIdInfo id: ATADEK-2023/16, briefTitle: The Validity and Reliability Study of Turkish Version of the Sense of Competence in Dementia Care Staff (SCIDS) Scale, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-03-10, primaryCompletionDateStruct date: 2024-07, completionDateStruct date: 2024-09, studyFirstPostDateStruct date: 2024-03-07, lastUpdatePostDateStruct date: 2024-03-07, sponsorCollaboratorsModule leadSponsor name: Yeditepe University, class: OTHER, collaborators name: Acibadem University, descriptionModule briefSummary: The purpose of the study is to adapt the SCIDS into the Turkish version and validate it in the social and cultural context of Turkey to assess staff competency in dementia care in the long-term care setting., conditionsModule conditions: Dementia, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 80, type: ESTIMATED, armsInterventionsModule interventions name: Questionnaire, outcomesModule primaryOutcomes measure: Sense of Competence in Dementia Care Staff (SCIDS) Scale, secondaryOutcomes measure: Caring Behaviors Inventory-24, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, hasResults: False
protocolSection identificationModule nctId: NCT06297746, orgStudyIdInfo id: am7mi3VB, briefTitle: Subvastus vs. Medial Parapatellar Approaches in Total Knee Arthroplasty With Quadriceps Muscle Elastography, statusModule overallStatus: COMPLETED, startDateStruct date: 2023-07-10, primaryCompletionDateStruct date: 2023-12-01, completionDateStruct date: 2023-12-01, studyFirstPostDateStruct date: 2024-03-07, lastUpdatePostDateStruct date: 2024-03-08, sponsorCollaboratorsModule leadSponsor name: Istanbul University - Cerrahpasa (IUC), class: OTHER, descriptionModule briefSummary: ABSTRACTINTRODUCTIONKnee osteoarthritis is a common joint pathology causing joint pain and ambulatory limitations. In primary total knee arthroplasty (TKA) surgeries, medial parapatellar (MP) and subvastus (SV) approaches are frequently used. The MP approach provides good exposure and is more widely used. In the SV approach, the vastus medialis muscle is preserved. Some argue that the extensor mechanism may heal earlier with the SV approach. In this study, unlike previous studies, the investigators aimed to quantitatively compare the early outcomes of MP and SV approaches, through shear wave elastography (SWE) measurements isolated over the vastus medialis and vastus lateralis muscles.MATERIALS AND METHODSThe study included 20 patients with indications for TKA due to primary osteoarthritis, divided into MP and SV groups. SWE measurements of the vastus medialis and vastus lateralis muscles were performed preoperatively and at 3-month follow-up. Clinical scores (Knee Society Score and WOMAC) and straight leg raising time were recorded both preoperatively and postoperatively., conditionsModule conditions: Total Knee Arthroplasty, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: CROSSOVER, primaryPurpose: TREATMENT, maskingInfo masking: DOUBLE, whoMasked: PARTICIPANT, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 20, type: ACTUAL, armsInterventionsModule interventions name: Subvastus approach, interventions name: Medial Parapatellar approach, outcomesModule primaryOutcomes measure: Shear wave values, eligibilityModule sex: ALL, stdAges: CHILD, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Istanbul University - Cerrahpasa, Cerrahpasa Faculty of Medicine, city: Istanbul, state: Fatih, zip: 34098, country: Turkey, geoPoint lat: 41.01384, lon: 28.94966, hasResults: False
protocolSection identificationModule nctId: NCT06297720, orgStudyIdInfo id: 2401110013, briefTitle: Early Oral Hydration After Thoracoscopic Surgery, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-03-01, primaryCompletionDateStruct date: 2025-02-28, completionDateStruct date: 2025-06-30, studyFirstPostDateStruct date: 2024-03-07, lastUpdatePostDateStruct date: 2024-03-07, sponsorCollaboratorsModule leadSponsor name: Chang Gung Memorial Hospital, class: OTHER, descriptionModule briefSummary: The goal of this clinical trial is to learn about the safety and feasibility of early oral hydration in patients receiving video-assisted thoracoscopic surgery after general anesthesia. The main questions aims to answer:* the safety and feasibility of oral hydration supplementation in the recovery room following general anesthesia.* the degree of improvement in sore throat and dry mouth after oral hydration.* the side effects and risks of oral hydration supplementation, such as the incidence of postoperative nausea and vomiting.* the impact of oral hydration supplementation in the recovery room following general anesthesia on hemodynamics.* patient satisfaction with oral hydration supplementation in the recovery room following general anesthesia.Participants will receive a series of oral hydration from swab moistening, and ice cube hydration to water hydration in the recovery room. Researchers will compare with the standard, no-hydration group to see if it is safe and feasible to hydrate patients in the recovery room., conditionsModule conditions: Anesthesia, conditions: Intubation Complication, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 120, type: ESTIMATED, armsInterventionsModule interventions name: Oral hydration, outcomesModule primaryOutcomes measure: sore throat level by VAS (Visual Analogue Scale), primaryOutcomes measure: Mouth dryness, secondaryOutcomes measure: post-operative nausea and vomiting (PONV), secondaryOutcomes measure: timing of post-operative nausea and vomiting (PONV), secondaryOutcomes measure: duration of post-operative nausea and vomiting (PONV), secondaryOutcomes measure: management of post-operative nausea and vomiting (PONV), secondaryOutcomes measure: Heart Rate in PACU (Postanesthesia Care Unit), secondaryOutcomes measure: Blood pressure in PACU (Postanesthesia Care Unit), secondaryOutcomes measure: Patient's satisfaction, eligibilityModule sex: ALL, minimumAge: 20 Years, maximumAge: 70 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: ChangGung MH, city: Taoyuan, zip: 33380, country: Taiwan, contacts name: JUN-YU CHEN, role: CONTACT, geoPoint lat: 24.95233, lon: 121.20193, hasResults: False
protocolSection identificationModule nctId: NCT06297707, orgStudyIdInfo id: P.T.REC/012/005044, briefTitle: Effect of Aquatic High Intensity Resistive Training on Patients With Chronic Heart Failure, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-03-05, primaryCompletionDateStruct date: 2025-03-30, completionDateStruct date: 2025-12-30, studyFirstPostDateStruct date: 2024-03-07, lastUpdatePostDateStruct date: 2024-03-07, sponsorCollaboratorsModule leadSponsor name: Cairo University, class: OTHER, descriptionModule briefSummary: PURPOSE:to evaluate effect of aquatic high intensity resistive training on cardiac function and exercise capacity in patients with chronic heart failure.BACKGROUND:Heart failure (HF) is a rapidly growing public health issue with an estimated prevalence of \>37.7 million individuals globally. HF is a shared chronic phase of cardiac functional impairment secondary to many etiologies, and patients with HF experience numerous symptoms that affect their quality of life, including dyspnea, fatigue, poor exercise tolerance, and fluid retention., conditionsModule conditions: Heart Failure, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: DOUBLE, whoMasked: PARTICIPANT, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 60, type: ESTIMATED, armsInterventionsModule interventions name: aquatic high intensity resistive training, interventions name: usual care, outcomesModule primaryOutcomes measure: Cardiac function, secondaryOutcomes measure: exercise capacity, secondaryOutcomes measure: physical symptoms of heart failure, eligibilityModule sex: ALL, minimumAge: 45 Years, maximumAge: 60 Years, stdAges: ADULT, contactsLocationsModule locations facility: Faculty of Physical Therapy, status: RECRUITING, city: Cairo, state: Dokki, zip: 11432, country: Egypt, contacts name: marwa M elsayed, phd, role: CONTACT, phone: 01156033818, phoneExt: 02, email: marwadd999@gmail.com, contacts name: marwa M elsayed, ph.d, role: CONTACT, phone: 01156033818, phoneExt: 02, email: marwadd999@gmail.com, geoPoint lat: 30.06263, lon: 31.24967, hasResults: False
protocolSection identificationModule nctId: NCT06297694, orgStudyIdInfo id: PamukkaleU., briefTitle: Clinical Interpretation and Cutoff Scores for ABILHAND Questionnaire in Rheumatoid Arthritis, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-03, primaryCompletionDateStruct date: 2024-06, completionDateStruct date: 2024-07, studyFirstPostDateStruct date: 2024-03-07, lastUpdatePostDateStruct date: 2024-03-07, sponsorCollaboratorsModule leadSponsor name: Pamukkale University, class: OTHER, descriptionModule briefSummary: In individuals with rheumatoid arthritis, the most significant symptom is the loss of manual ability and function in the hands. In rheumatoid arthritis, where patient-reported assessment scales are frequently used, hand skills should be evaluated with an ideal questionnaire that best represents hand activities. The ABILHAND-RA questionnaire possesses all these features, being a short and easily fillable survey. The aim is to determine of clinically significant cutoff scores for perceived manual ability evaluated by ABILHAND corresponding to observed and perceived upper extremity assessments in individuals with rheumatoid arthritis., conditionsModule conditions: Rheumatoid Arthritis, designModule studyType: OBSERVATIONAL, designInfo observationalModel: CASE_ONLY, timePerspective: CROSS_SECTIONAL, enrollmentInfo count: 156, type: ESTIMATED, outcomesModule primaryOutcomes measure: Disease Activity Score (DAS 28), primaryOutcomes measure: Nine hole peg test, primaryOutcomes measure: Hand grip strength, eligibilityModule sex: ALL, minimumAge: 20 Years, maximumAge: 65 Years, stdAges: ADULT, stdAges: OLDER_ADULT, hasResults: False
protocolSection identificationModule nctId: NCT06297681, orgStudyIdInfo id: 2023-1-27-2, briefTitle: Combination of Daratumumab and BD Regimen and Dapagliflozin in the Treatment of M-protein Related Cardiac Disease, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-03-15, primaryCompletionDateStruct date: 2025-01-30, completionDateStruct date: 2025-12-31, studyFirstPostDateStruct date: 2024-03-07, lastUpdatePostDateStruct date: 2024-03-07, sponsorCollaboratorsModule leadSponsor name: Beijing Chao Yang Hospital, class: OTHER, collaborators name: Beijing Chuiyangliu Hospital, collaborators name: Beijing Boren Hospital, descriptionModule briefSummary: It is expected to include 40 patients with M-protein related cardiac disease. The treatment medication for enrolled patients must comply with the treatment regimen of Daratumumab + Bortezomib + Dexamethasone. All patients were given Dapagliflozin 10mg/day at the beginning of treatment (creatinine clearance rate greater than 20ml/min)., conditionsModule conditions: M-protein Related Cardiac Disease, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: CROSS_SECTIONAL, enrollmentInfo count: 40, type: ESTIMATED, armsInterventionsModule interventions name: Daratumumab + Bortezomib + Dexamethasone + Dapagliflozin, outcomesModule primaryOutcomes measure: Objective response rate (ORR), secondaryOutcomes measure: 2-year PFS rate, progression free survival (PFS), secondaryOutcomes measure: 2-year OS rate, overall survival (OS), secondaryOutcomes measure: Duration of Relief (DOR), secondaryOutcomes measure: Next treatment time (TTNT), eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, hasResults: False